Discounted Cash Flow (DCF) Analysis Levered
Abeona Therapeutics Inc. (ABEO)
$3.41
+0.13 (+3.96%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.84 | 3 | 10.74 | 38.46 | 137.77 | 493.46 | 1,767.51 | 6,330.95 | 22,676.44 | 81,223.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -22.93 | -39.11 | -62.82 | -35.02 | -65.66 | -4,706.10 | -16,856.51 | -60,377.32 | -216,261.91 | -774,615.53 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.86 | -19.49 | -6.51 | -1.34 | -4.15 | -809.35 | -2,898.98 | -10,383.68 | -37,192.67 | -133,218.19 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -23.79 | -58.61 | -69.33 | -36.36 | -69.82 | -5,515.46 | -19,755.49 | -70,761 | -253,454.58 | -907,833.72 |
Weighted Average Cost Of Capital
| Share price | $ 3.41 |
|---|---|
| Beta | 1.079 |
| Diluted Shares Outstanding | 3.94 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 39.13% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.708 |
| Total Debt | 9.38 |
| Total Equity | 13.43 |
| Total Capital | 22.81 |
| Debt Weighting | 41.12 |
| Equity Weighting | 58.88 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.84 | 3 | 10.74 | 38.46 | 137.77 | 493.46 | 1,767.51 | 6,330.95 | 22,676.44 | 81,223.37 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.93 | -39.11 | -62.82 | -35.02 | -65.66 | -4,706.10 | -16,856.51 | -60,377.32 | -216,261.91 | -774,615.53 |
| Capital Expenditure | -0.86 | -19.49 | -6.51 | -1.34 | -4.15 | -809.35 | -2,898.98 | -10,383.68 | -37,192.67 | -133,218.19 |
| Free Cash Flow | -23.79 | -58.61 | -69.33 | -36.36 | -69.82 | -5,515.46 | -19,755.49 | -70,761 | -253,454.58 | -907,833.72 |
| WACC | ||||||||||
| PV LFCF | -101.87 | -44.07 | -69.82 | -4,549.96 | -13,444.33 | -39,725.66 | -117,382.41 | -346,844.58 | ||
| SUM PV LFCF | -521,946.94 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 21.22 |
| Free cash flow (t + 1) | -925,990.40 |
| Terminal Value | -4,817,848.06 |
| Present Value of Terminal Value | -1,840,694.44 |
Intrinsic Value
| Enterprise Value | -2,362,641.39 |
|---|---|
| Net Debt | -23.56 |
| Equity Value | -2,362,617.83 |
| Shares Outstanding | 3.94 |
| Equity Value Per Share | -600,003.04 |